2 suspended. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Suspended 2 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma Single dose injection of certain dose of UWD-00B, MMF Immunosuppression - Multiple Myleoma, Refractory and Relapsed Multiple Myeloma | Early Phase 1 | Suspended | Wondercel Biotech (ShenZhen) | 30 | 2025-07-01 | 2026-05-07 |
| A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma. ESO-T01 Injection - Multiple Myeloma | Early Phase 1 | Suspended | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2024-11-18 | 2026-07-22 |
Multiple Myeloma (2)
Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Vascular Diseases (2)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Wondercel Biotech (ShenZhen) (1)
China (2)